Improving healthcare delivery in hospitals by optimized utilization of medicines

A digital future for value added medicines

Calls to action to improve access to value added medicines

Case Studies for Value Added Medicines. Unlocking the potential of patient-centric continuous innovation

Addressing medicine shortages in Europe

2017 Market Review – Biosimilar Medicines Markets – Policy Overview

Value Added Medicines: Time to Adjust the HTA Decision Frameworks

Global Healthcare Trends and Outlook

The Impact of Biosimilar Competition in Europe

ISPOR 2016 EU – Value Added Medicines

ispor2

Healthcare System Inefficiencies Related To Medicines: Any Potential Room For Improvement?

OPEN

ispor3

Value Added Medicines: The Need to Establish One Common Terminology for Repurposed Medicines

OPEN

ispor4

Value Added Medicines: What Value Repurposed Medicines Might Bring to Society?

OPEN

ispor5

Obstacles for Adoption of Value Added Medicines: Call for Policy Changes for Value Recognition of Repurposed Medicines

OPEN